A study of abrocitinib for children ages 6–11 with eczema
Treatments studied
Part of Skin clinical trials.
This trial tests a daily pill called Abrocitinib to see if it can help children ages 6 to 11 with moderate-to-severe eczema that hasn't gotten better with creams or ointments. Eczema (also called atopic dermatitis) causes itchy, red skin, and this medicine might calm the immune response to reduce itching and rashes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 11 years old.
- They must have had eczema for at least 1 year, and it must be moderate to severe (covering at least 10% of their body with frequent itching).
- They must have tried prescription creams or ointments for eczema that did not work well enough.
- Your child must weigh at least 15 kg (about 33 pounds).
- They cannot have certain infections, skin conditions (like psoriasis), or a history of blood-clotting problems. They should not have received a live vaccine in the last 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Eczema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.